Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort.

There was a strong trend toward a reduced mortality in the baricitinib group compared to the tocilizumab group, significant reduction of progression to mechanical ventilation and a significant shorter length of stay of survivors (for details see supplemental Table 1 ).

also in 5,725 other papers